SCHEMBL1801294

SCHEMBL1801294

C/C=N/N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1618117 1.00
SCHEMBL9640026 1.00
SCHEMBL18698926 0.71
SCHEMBL10425866 0.67
SCHEMBL952545 0.59
SCHEMBL10049422 0.59
SCHEMBL366648 0.59
SCHEMBL427297 0.59
SCHEMBL4891353 0.59
SCHEMBL834860 0.59

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0820454-B1 ANELLATED BETA-CARBOLINES SCHERING AG (DE) 2002-07-24 EP claimed
US-6127368-A ANXIOLYTIC AND NOOTROPIC AGENTS, COGNITION ACTIVATORS SCHERING AKTIENGESELLSCHAFT (DE) 2000-10-03 US claimed
US-20230000836-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PURDUE RESEARCH FOUNDATION 2023-01-05 US disclosed
US-11344623-B2 Cholecystokinin B receptor targeting for imaging and therapy PURDUE RESEARCH FOUNDATION (US) 2022-05-31 US disclosed
CN-111378270-B Composition for forming foam, method for producing foam, and material for leather 日华化学株式会社 2022-05-06 CN disclosed
US-11318121-B2 PSMA binding ligand-linker conjugates and methods for using PURDUE RESEARCH FOUNDATION (US) 2022-05-03 US disclosed
US-20210322388-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PURDUE RESEARCH FOUNDATION 2021-10-21 US disclosed
US-20210024581-A1 CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS ENDOCYTE INC (US) 2021-01-28 US disclosed
US-20200384114-A1 CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY PURDUE RESEARCH FOUNDATION 2020-12-10 US disclosed
US-10828282-B2 PSMA binding ligand-linker conjugates and methods for using PURDUE RESEARCH FOUNDATION (US) 2020-11-10 US disclosed
US-10765756-B2 Cholecystokinin B receptor targeting for imaging and therapy PURDUE RESEARCH FOUNDATION (US) 2020-09-08 US disclosed
EP-1924563-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 F.HOFFMANN-LA ROCHE AG (CH) 2008-05-28 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20070191394-A1 Antibacterial agents WARNER-LAMBERT COMPANY LLC 2007-08-16 US disclosed
US-20070123711-A1 Synthesis methods and intermediates for the manufacture of rizatriptan RATIOPHARM GMBH (DE) 2007-05-31 US disclosed
EP-1763398-A1 SUPPORT-COLOURING MEANS Doublet, Luc (FR) 2007-03-21 EP disclosed
WO-2007025892-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 F. HOFFMANN-LA ROCHE AG (CH) 2007-03-08 WO disclosed
WO-2005115613-A1 SUPPORT-COLOURING MEANS DOUBLET SA (FR) 2005-12-08 WO disclosed
US-6127368-A ANXIOLYTIC AND NOOTROPIC AGENTS, COGNITION ACTIVATORS SCHERING AKTIENGESELLSCHAFT (DE) 2000-10-03 US disclosed
WO-1999040062-A1 HYDRAZONE DERIVATIVES NOVO NORDISK A/S (DK) 1999-08-12 WO disclosed